Active, not recruitingPhase 3NCT05899673

An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

Studying Alpha-1-antitrypsin deficiency

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Takeda
Principal Investigator: Study Director
Takeda
Intervention: Fazirsiran Injection(drug)
Enrollment: 31 enrolled
Eligibility: 18 years · All sexes
Timeline: 2023 – 2033

Study locations (10)

UCSD Altman Clinical and Translational Research Institute, La Jolla, California, United States
Stanford Medicine Outpatient Center, Redwood City, California, United States
UF Clinical and Translational Science Institute, Gainesville, Florida, United States
University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States
Medical University of South Carolina - Hollings Cancer Center - PPDS, Charleston, South Carolina, United States
Medizinische Universitat Wien (Medical University of Vienna), Vienna, Austria
Universitätsklinikum der RWTH Aachen, Aachen, North Rhine-Westphalia, Germany
Hospital Nélio Mendonça, Funchal, Portugal
Addenbrooke's Hospital, Cambridge, United Kingdom
Royal Infirmary of Edinburgh - PPDS, Edinburgh, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05899673 on ClinicalTrials.gov

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

See all trials for Alpha-1-antitrypsin deficiency →

← Back to all trials